Clinical Characteristics and Treatment Outcomes of Mild to Moderate Covid-19 Patients in Saudi Arabia: A Single Centre Study
Albanghali et al.,
Clinical Characteristics and Treatment Outcomes of Mild to Moderate Covid-19 Patients in Saudi Arabia: A..,
Journal of Infection and Public Health, doi:10.1016/j.jiph.2022.02.001
Retrospective 811 hospitalized COVID+ patients in Saudi Arabia, showing higher mortality with HCQ treatment in unadjusted results subject to
confounding by indication.
This study is excluded in the after exclusion results of meta
analysis:
unadjusted results with no group details; substantial unadjusted
confounding by indication likely.
risk of death, 34.6% higher, RR 1.35, p = 0.46, treatment 20 of 466 (4.3%), control 11 of 345 (3.2%).
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Albanghali et al., 3 Feb 2022, retrospective, Saudi Arabia, peer-reviewed, 8 authors.
Abstract: Journal Pre-proof
Clinical Characteristics and Treatment Outcomes of
Mild to Moderate Covid-19 Patients in Saudi
Arabia: A Single Centre Study
Mohammad Albanghali, Saleh Alghamdi,
Mohammed Alzahrani, Bassant Barakat, Abdul
Haseeb, Jonaid Ahmad Malik, Sakeel Ahmed,
Sirajudheen Anwar
PII:
S1876-0341(22)00034-X
DOI:
https://doi.org/10.1016/j.jiph.2022.02.001
Reference:
JIPH1808
To appear in: Journal of Infection and Public Health
Received date: 12 June 2021
Revised date: 29 January 2022
Accepted date: 1 February 2022
Please cite this article as: Mohammad Albanghali, Saleh Alghamdi, Mohammed
Alzahrani, Bassant Barakat, Abdul Haseeb, Jonaid Ahmad Malik, Sakeel Ahmed
and Sirajudheen Anwar, Clinical Characteristics and Treatment Outcomes of
Mild to Moderate Covid-19 Patients in Saudi Arabia: A Single Centre Study,
Journal
of
Infection
and
Public
Health, (2021)
doi:https://doi.org/10.1016/j.jiph.2022.02.001
This is a PDF file of an article that has undergone enhancements after acceptance,
such as the addition of a cover page and metadata, and formatting for readability,
but it is not yet the definitive version of record. This version will undergo
additional copyediting, typesetting and review before it is published in its final
form, but we are providing this version to give early visibility of the article.
Please note that, during the production process, errors may be discovered which
could affect the content, and all legal disclaimers that apply to the journal pertain.
© 2021 Published by Elsevier.
Clinical Characteristics and Treatment Outcomes of Mild to Moderate Covid-19 Patients
in Saudi Arabia: A Single Centre Study
Mohammad Albanghali1, Saleh Alghamdi2, Mohammed Alzahrani3, Bassant Barakat2, Abdul
1
Department of Public Health, Faculty of Applied Medical Sciences, Albaha University,
pr
Albaha, Saudi Arabia; email: mohammad.aref@bu.edu.sa
2
oo
f
Haseeb4, Jonaid Ahmad Malik5 , Sakeel Ahmed6 , Sirajudheen Anwar7*
Department of Clinical Pharmacy, Faculty of Clinical Pharmacy, Albaha University,
3
e-
Albaha, Saudi Arabia; email: bbarakat@bu.edu.sa , saleh.alghamdi@bu.edu.sa
Pharmaceutical care services department, King Fahad Hospital, Albaha, Saudi Arabia;
4
Pr
email: malzahrani172@moh.gov.sa
Department of Clinical pharmacy, College of Pharmacy, Umm Al Qura University,
Makkah, Saudi Arabia; email: amhaseeb@uqu.edu.sa
Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education
al
5
6
ur
n
and Research, Guwahati, India
Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education
and Research, Mohali, India
Department of Pharmacology and Toxicology, College of Pharmacy, University of Hail,
Jo
7
Hail, Saudi Arabia; email: si.anwar@uoh.edu.sa
Running title: Clinical Outcomes in mild COVID-19 patients.
* Corresponding author:
Dr. Sirajudheen Anwar,
Department of Pharmacology and Toxicology,
College of Pharmacy, University of Hail, Hail, Saudi Arabia
E-mail address: (si.anwar@uoh.edu.sa)
1
Abstract
Objective: Since the severity of symptoms affects the treatment option for Coronavirus Disease
2019 (COVID-19) patients, the treatment pattern for mild to moderate non-ICU cases must be
evaluated, particularly in the current scenario of mutation and variant strain for effective decision
making. Methods: The objective of retrospective analysis was to assess clinical and treatment
oo
f
outcomes in mild to moderate symptoms in non-ICU patients with COVID-19..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit